Quick Answer
PDS Biotechnology Corp reported Operating Income of -$31.54 million for fiscal year 2025.
PDS Biotechnology Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$31.54M | +13.2% |
| 2024 | -$36.32M | +15.6% |
| 2023 | -$43.05M | -3.3% |
| 2022 | -$41.67M | -94.4% |
| 2021 | -$21.44M | -43.9% |
| 2020 | -$14.90M | +29.2% |
| 2019 | -$21.03M | -476.9% |
| 2018 | -$3.65M | +93.0% |
| 2017 | -$51.97M | -31.5% |
| 2016 | -$39.51M | -49.1% |
| 2015 | -$26.50M | -100.8% |
| 2014 | -$13.19M | -103.4% |
| 2013 | -$6.49M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.14M | +20.0% | -6.8% |
| June 30, 2025 | -$7.62M | +12.2% | +16.3% |
| March 31, 2025 | -$9.11M | +9.8% | +10.5% |
| September 30, 2024 | -$10.18M | +3.2% | -17.2% |
| June 30, 2024 | -$8.68M | +31.6% | +14.0% |
| March 31, 2024 | -$10.10M | -7.2% | +4.0% |
| September 30, 2023 | -$10.52M | -44.5% | +17.1% |
| June 30, 2023 | -$12.70M | -79.0% | -34.7% |
- PDS Biotechnology Corp showed an increase of +13.2% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, PDS Biotechnology Corp’s operating income has declined by 386.2% (from -$6.49 million to -$31.54 million).
- The most recent figure is from PDS Biotechnology Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: